ClinicalTrials.gg
Not yet recruitingNCT07945691Updated Nov 18, 2026

Imaging Follow-up After Stone Treatment

An interventional study of kidney, ureter, bladder ultrasound and kidney, ureter, bladder ultrasound in Lithiasis, Urinary, Stone, Urinary and Lithotripsy, sponsored by National and Kapodistrian University of Athens. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionUrinary CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Calculi
Why
  1. The study's listed conditions name Urinary Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National and Kapodistrian University of Athens · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Kidney stones are a common condition that can recur even after successful treatment. Regular imaging tests can help detect new stones, but frequent use of X-rays and CT scans can expose patients to unnecessary radiation. It is not yet clear how often patients should have imaging tests after treatment.

This study compares two schedules for monitoring patients who have undergone treatment for kidney stones and have no significant remaining stones. Participants are randomly assigned to one of two groups. One group has an ultrasound examination of the kidneys and urinary tract every 6 months, while the other group has the same examination every 12 months.

The study aims to determine whether more frequent ultrasound examinations can reduce unexpected episodes related to kidney stones, such as pain, bleeding in the urine, or urinary infections caused by blocked urine flow.

The researchers will also assess changes in kidney function, visits to the emergency department, the number of imaging tests performed, the development or growth of stones without symptoms, and the overall cost of imaging.

The study includes adults with a low or high risk of kidney stones recurrence and is conducted at Sismanoglio General Hospital in Athens, Greece.

The findings may help determine an appropriate schedule for monitoring patients after kidney stone treatment while reducing unnecessary tests, radiation exposure, and healthcare costs.

02

Conditions studied

  • Lithiasis, Urinary
  • Stone, Urinary
  • Lithotripsy
  • Ultrasound
  • Follow-up

Browse trials for

03

In context

Urinary Calculi Reclassified

96 studies on the registry are indexed under Urinary Calculi; 21 are open to participants now.

This study's planned enrollment of 160 is above the median of 120 across 63 interventional studies indexed under Urinary Calculi.

Browse Urinary Calculi studies →

Lead sponsor

National and Kapodistrian University of Athens is the lead sponsor of 178 studies on the registry; 56 are open to participants now.

Compared within Urinary Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older, including both males and females.
  • Patients with urolithiasis of any stone composition.
  • Patients with stones at any anatomical location.
  • Patients undergoing any definitive stone treatment procedure, including extracorporeal shock wave lithotripsy (SWL), ureteroscopy (URS), retrograde intrarenal surgery (RIRS), or percutaneous nephrolithotomy (PCNL).
  • Patients classified as either low-risk or high-risk for stone recurrence according to European Association of Urology (EAU) criteria.
  • Patients with no significant residual stone fragments following treatment, defined as the absence of residual fragments larger than 2 mm at 4-6 weeks after the procedure, assessed by radiography and ultrasound or low-dose computed tomography.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study.
  • Patients with anatomical abnormalities or a history of previous open surgery for stone disease.
  • Patients with a solitary kidney or chronic kidney disease.
  • Patients with occupations considered to be associated with a high risk of stone disease, such as pilots.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    6-monthly ultrasound follow-up

    Diagnostic Test: kidney, ureter, bladder ultrasound

  • Active comparator
    12-monthly ultrasound follow-up

    Diagnostic Test: kidney, ureter, bladder ultrasound

Interventions

  • Diagnostic testkidney, ureter, bladder ultrasound

    kidney, ureter, bladder ultrasound every 6 months

  • Diagnostic testkidney, ureter, bladder ultrasound

    kidney, ureter, bladder ultrasound every 12 months

06

What researchers measure

Primary outcomes

  1. Incidence of Symptomatic Stone Episodes

    Occurrence of symptomatic stone episodes during a one-year follow-up period, defined as any of the following: a new episode of renal colic or pain, hematuria not attributable to another cause, or urinary tract infection associated with obstruction caused by a newly formed stone. In patients with no visible residual stone fragments after treatment, the detection of any stone during follow-up will be considered recurrence. In patients with residual fragments smaller than 2 mm, detection of any fragment measuring 3 mm or larger will be considered recurrence.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

Secondary outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR)

    Change in estimated glomerular filtration rate (eGFR) during the follow-up period, as an indicator of changes in kidney function.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

  2. Number of Emergency Department Visits

    Number of visits to the emergency department during the follow-up period.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

  3. Number of Imaging Examinations Performed

    Total number of imaging examinations performed during the follow-up period for the evaluation of urolithiasis, including plain radiographs, computed tomography scans, and ultrasound examinations.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

  4. Incidence of Asymptomatic Stone Growth

    Number of patients who develop asymptomatic stone growth during the follow-up period, as detected by imaging examinations.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

  5. Total Cost of Imaging Examinations

    Total cost of imaging examinations performed during the follow-up period for the evaluation and monitoring of urolithiasis.

    Time frame: from randomization until the end of follow-up period, 1 year after intervention

07

Study locations

1 site
  • 2nd Department of Urology, Sismanoglio General Hospital
    Athens, Attica 15126, Greece
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 32 interventional studies with no phase under Urinary Calculi, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 79. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2027
CompletionEst.
Jan 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945691
Collaborators
Sismanoglio General Hospital
Responsible party
Panagiotis Neofytou (Principal Investigator, National and Kapodistrian University of Athens) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Panagiotis Neofytou
Contact
neo.panagiotis@gmail.com
00306996288898
Lazaros Tzelves
Contact
lazarostzelves@gmail.com
00306944104974

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion